Skip to main content

Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment

Neuroscience Bulletin volume 39, pages 170–172 (2023)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Li Z, Ruan M, Chen J, Fang Y. Major depressive disorder: Advances in neuroscience research and translational applications. Neurosci Bull 2021, 37: 863–880.

    Article  Google Scholar 

  2. Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 2016, 3: 619–627.

    Article  Google Scholar 

  3. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 2021, 78: 481–489.

    Article  Google Scholar 

  4. Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med 2022, 28: 844–851.

    Article  CAS  Google Scholar 

  5. Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 2021, 109: 2535–2544.e4.

    Article  CAS  Google Scholar 

  6. Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell 2021, 184: 2779–2792.e18.

    Article  CAS  Google Scholar 

  7. Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a hallucinogen-activated gq-coupled 5-HT 2A serotonin receptor. Cell 2020, 182: 1574–1588.e19.

    Article  CAS  Google Scholar 

  8. Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021, 589: 474–479.

    Article  CAS  Google Scholar 

  9. Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science 2022, 375: 403–411.

    Article  CAS  Google Scholar 

  10. Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 2013, 493: 532–536.

    Article  CAS  Google Scholar 

  11. Tye KM, Mirzabekov JJ, Warden MR, Ferenczi EA, Tsai HC, Finkelstein J, et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493: 537–541.

    Article  CAS  Google Scholar 

  12. Commons KG, Cholanians AB, Babb JA, Ehlinger DG. The rodent forced swim test measures stress-coping strategy, not depression-like behavior. ACS Chem Neurosci 2017, 8: 955–960.

    Article  CAS  Google Scholar 

  13. Schmack K, Bosc M, Ott T, Sturgill JF, Kepecs A. Striatal dopamine mediates hallucination-like perception in mice. Science 2021, 372: eabf4740.

    Article  CAS  Google Scholar 

  14. Marshel JH, Kim YS, Machado TA, Quirin S, Benson B, Kadmon J, et al. Cortical layer-specific critical dynamics triggering perception. Science 2019, 365: eaaw5202.

    Article  CAS  Google Scholar 

  15. Service RF. Psychedelics without hallucinations? Science 2022, 375: 370.

    Article  CAS  Google Scholar 

  16. Osman S. A mind-changing approach to the therapeutic use of psychedelics. Nat Struct Mol Biol 2022, 29: 189.

    Article  CAS  Google Scholar 

  17. Morgan CJA, Curran HV, Drugs ISCO. Ketamine use: A review. Addiction 2012, 107: 27–38.

    Article  Google Scholar 

Download references

Acknowledgements

This Research Highlight was supported by grants from the National Natural Science Foundation of China (82090032 and 31830033), the Key Area Research and Development Program of Guangdong Province (2018B030334001 and 2018B030340001), Guangdong Basic and Applied Basic Research Foundation (2020A1515110565), and the Science and Technology Program of Guangzhou (202007030013).

Author information

Authors and Affiliations

  1. State Key Laboratory of Organ Failure Research, Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorders, Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China

    Ya-Nan Yin & Tian-Ming Gao

Authors
  1. Ya-Nan Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tian-Ming Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tian-Ming Gao.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yin, YN., Gao, TM. Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment. Neurosci. Bull. 39, 170–172 (2023). https://doi.org/10.1007/s12264-022-00933-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-022-00933-7